Načítá se...
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient’s T cells with CD19-expressing tumour cells. Clinical trials have demonstra...
Uloženo v:
| Vydáno v: | Hum Vaccin Immunother |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605719/ https://ncbi.nlm.nih.gov/pubmed/30380973 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1540828 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|